CervoMed Inc.
Close on Oct 19, 2026
- Market cap
- $23.66M
- P/E (TTM)
- –
- Dividend yield
- –
About CervoMed
Pharmaceutical Preparations, SIC 2834
CervoMed Inc. is a clinical-stage biotechnology company focused on developing therapies for age-related degenerative brain disorders. The company's lead drug candidate, neflamapimod, is an orally administered small-molecule inhibitor of the p38α enzyme designed to reduce neuroinflammation, reverse synaptic dysfunction, and slow neuron degeneration. Its pipeline addresses diseases of the central nervous system, with its primary clinical focus on dementia with Lewy bodies. It also evaluates neflamapimod in clinical studies for conditions such as non-fluent variant primary progressive aphasia, recovery after stroke, and amyotrophic lateral sclerosis. The company targets patients experiencing synaptic deficits before irreversible neuronal loss occurs.
Operating within the biotechnology sector, the company conducts multiple clinical trial programs across its targeted indications. CervoMed maintains its principal executive offices in Boston, Massachusetts, and is incorporated under the laws of Delaware.
Summary of the business section of CervoMed's latest annual report, written by StockData.
Company profile
Company
- Legal name
- CervoMed Inc.
- Headquarters
- Boston, MA
- Address
- 20 Park Plaza, Suite 424 02116
- Phone
- (617) 744-4400
- Employees
- 15, Dec 31, 2024
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- RSM US LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- CRVO
- Exchange
- Nasdaq
- Shares outstanding
- 15M, Aug 6, 2026
- Public float
- $39.90M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-1.5 reverse, Aug 17, 2023; 1-for-50 reverse, Apr 19, 2022; 1-for-15 reverse, Mar 19, 2019; 1-for-15 reverse, Dec 14, 2018; 1-for-10 reverse, Nov 14, 2016; 1-for-10 reverse, Aug 19, 2016; 1-for-100 reverse, Mar 10, 2014; 1-for-100 reverse, Mar 7, 2014
- SEC CIK
- 1053691
- CUSIP
- 15713L109
- ISIN
- US15713L1098
- LEI
- 549300I3DV7F8OXPNA12
- EIN
- 30-0645032
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| John J. Alam | CEO & President, Director | 1,496,578 |
| Matthew Winton | Chief Commercial and Business | 15,000 |
| Rosch Mark De | EVP, RA and GA and PgM | – |
| Kelly Blackburn | EVP, Clinical Development | 13,674 |
| William Robert Elder | CFO, GC & Secretary | 12,500 |
| Robert Joseph Cobuzzi Jr. | Chief Operating Officer | 1,616 |
| Joshua S. Boger | Director | 2,012,682 |
| Frank Zavrl | Director | 353,009 |
| Jane H. Hollingsworth | Director | 943 |
| Jeffrey V. Poulton | Director | – |
| Marwan Sabbagh | Director | – |
| David Quigley | Director | – |
| Sylvie Gregoire | Director | 1,496,578 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Dr. Alam | $1.05M | $1.52M | $669.41K | $104 | – |
| FY2024 Dr. Alam | $1.04M | $953.31K | $732.49K | $31 | – |
| FY2023 Dr. Alam | $1.52M | $1.37M | $467.05K | $101 | – |
| FY2022 | $1.42M | $1.30M | $400.73K | $33 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2024, we had fifteen employees, all of whom we classify as full-time employees, up from eight employees as of December 31, 2023.”
Corporate history
Events identified from SEC filings